Insulin Resistance and Prediabetes: Understanding the Overlooked In-Between Stage
Insulin resistance is not a standalone condition with clear symptoms, but a slowly progressing state in which the body's cells respond less effectively to the hormone insulin. Prediabetes is the measurable in-between stage that can develop from it: blood sugar is elevated, but still below the threshold for type 2 diabetes. It is precisely this gray zone that is often overlooked, because it causes hardly any complaints – according to data from the US health authority CDC, the majority of those affected are unaware of it. This article explains soberly what lies behind these terms, what the research actually shows, and what role the much-discussed GLP-1 peptides play – without promises of a cure and without instructions for action. It does not replace a medical assessment, but is intended to make the topic easier to understand and put it in context.
Machine-assisted translation. The German original is the authoritative version.
Key points
- Insulin resistance develops gradually and without symptoms; prediabetes is the measurable in-between stage before type 2 diabetes.
- According to CDC data, the large majority of those affected are unaware of their prediabetes – early detection usually only succeeds through blood tests.
- GLP-1 peptides such as Semaglutid and Tirzepatid are approved, prescription-only medicines and are supported by human data in high-risk groups – not a lifestyle shortcut for everyone.
- In the SURMOUNT-1 study, the transition to type 2 diabetes fell markedly, but after discontinuation the risk converged again; a lasting effect is not assured.
- The best-evidenced and medication-independent lever against insulin resistance remains lifestyle; elevated values belong in medical hands.
What insulin resistance and prediabetes actually mean
Insulin is the hormone that ushers sugar (glucose) out of the blood and into the cells, where it is used as energy or stored. In insulin resistance, muscle, liver and fat cells in particular respond less well to this signal. At first the pancreas compensates by producing more insulin – blood sugar stays normal for a long time, while insulin levels quietly rise in the background. Only when the pancreas can no longer keep up over time does sugar begin to accumulate in the blood.
This is the point at which prediabetes begins: blood sugar is higher than normal, but not yet high enough for a diagnosis of type 2 diabetes. Professional bodies and authorities such as the US NIDDK define this in-between stage using fixed laboratory ranges – for example a long-term sugar value (HbA1c) of 5.7 to 6.4 percent, a fasting blood sugar of 100 to 125 mg/dl, or certain values in the glucose tolerance test. Above that, one speaks of diabetes; below it, the value is considered normal. These limits are not a rigid truth, but conventions that reflect the risk well – the assessment in an individual case belongs in medical hands.
- Insulin resistance: cells respond less well to insulin, and the pancreas compensates by producing more
- Prediabetes: measurably elevated blood sugar, but still below the diabetes threshold
- Diagnostic reference points (NIDDK): HbA1c 5.7–6.4 %, fasting glucose 100–125 mg/dl
- Complaints are usually absent – which is why the condition goes unnoticed for a long time
Why this in-between stage is so often overlooked
The tricky thing about prediabetes is how inconspicuous it is. As a rule there are no noticeable symptoms, no pain, no clear warning sign. According to the CDC, around 96 million adults in the US – roughly one in three – have prediabetes, and about 80 percent of them do not know it. Internationally too, the prevalence is high and continues to rise. The condition is therefore often only discovered by chance, for instance during a routine check-up.
Risk factors that favor insulin resistance include excess weight – especially abdominal fat – lack of exercise, older age, a family history, as well as certain accompanying conditions such as polycystic ovary syndrome (PCOS) or sleep apnea. What matters is an honest assessment: prediabetes is a risk situation, not an inescapable fate. Studies and guidelines consistently emphasize that even moderate weight loss and more exercise can significantly slow or delay the progression to diabetes.
- CDC: roughly one in three adults in the US affected, about 80 % unaware
- Typical risk factors: abdominal fat, lack of exercise, age, family history, PCOS, sleep apnea
- Prediabetes is a risk situation, not inevitable diabetes
- Lifestyle changes can demonstrably delay the progression
The role of GLP-1 peptides: what the research actually shows
In recent years, so-called GLP-1 receptor agonists have come strongly into focus – agents modeled on a gut hormone produced by the body that influence, among other things, the feeling of satiety, gastric emptying and insulin secretion. Approved medicines in this class are Semaglutid and the dual agent Tirzepatid (which additionally acts on the GIP receptor). Both are approved in the EU and the US as prescription medicines for the treatment of type 2 diabetes and obesity respectively – not as freely available lifestyle products.
For the topic of prediabetes, robust human data are available. In the three-year SURMOUNT-1 study (in the New England Journal of Medicine, 2024/2025), 2,539 people with obesity were examined, including 1,032 with prediabetes. In the active-treatment group, significantly fewer participants developed type 2 diabetes over the treatment period than under placebo (around 1.3 % versus 13.3 %), accompanied by considerable weight loss. That is a strong signal – but it still needs to be put in context: what was studied was a specific high-risk group with obesity under medical supervision, and after discontinuation the diabetes risk in both groups converged again. Whether and for how long such an effect lasts is therefore by no means settled for everyone. The experimental triple agent Retatrutid is being examined in ongoing clinical trials, but is not yet approved.
- GLP-1 agents (e.g. Semaglutid, Tirzepatid): approved, prescription-only medicines – not a dietary supplement
- SURMOUNT-1: with obesity + prediabetes, markedly rarer transition to type 2 diabetes vs. placebo
- What was studied was a high-risk group under medical supervision – not the general population
- After discontinuation the risk converged again – a lasting effect is not assured
- Retatrutid is an investigational agent and (as of now) not approved
Risks, limits and an honest assessment of the hype
Considerable hype has built up around GLP-1 peptides, often promising more than the evidence supports. Claims from online communities that these substances are a convenient shortcut against insulin resistance for everyone are exactly that – claims, not proven facts. The approved uses concern clearly defined patient groups, and the agents are prescription-only for good reason: they can have side effects, most commonly gastrointestinal complaints, and their use belongs under medical supervision. Sources outside regulated supply are not only legally precarious, but also carry considerable quality and safety risks.
At the same time, the fundamentals must not be lost from view: the best-evidenced lever against insulin resistance and prediabetes remains lifestyle. Exercise, an improvement in diet, the reduction of excess weight and sufficient sleep improve insulin sensitivity – this has been well secured for decades by large prevention studies and is effective independently of any medication. Peptides do not replace this foundation; in medically indicated cases they can complement it. Anyone who suspects elevated blood sugar or risk factors should have it medically clarified, rather than relying on promises from the internet.
- Community promises of a 'shortcut for everyone' are claims, not proven facts
- The prescription requirement exists for a reason: possible side effects, necessary medical supervision
- Unregulated sources carry quality and safety risks
- The best-evidenced lever remains lifestyle: exercise, diet, weight, sleep
- With elevated blood sugar or risk factors: medical clarification rather than self-experimentation
Related substance profiles
Frequently asked questions
- Is prediabetes reversible?
- Prediabetes is a risk situation, not a final verdict. Authorities such as NIDDK and CDC emphasize that lifestyle measures – more exercise, a better diet, reduction of excess weight, sufficient sleep – can improve insulin sensitivity and delay or prevent the transition to type 2 diabetes. How far values can be normalized varies from person to person and should be medically supervised.
- Are GLP-1 peptides a remedy for insulin resistance?
- Semaglutid and Tirzepatid are approved, prescription-only medicines for type 2 diabetes and obesity respectively. Studies such as SURMOUNT-1 show a markedly rarer transition to diabetes in high-risk groups with obesity. That is no carte blanche for general use: the agents work in defined patient groups under medical supervision, have side effects and do not replace the lifestyle foundation. Claims that they are a shortcut for everyone are not proven.
- How can I tell whether I am affected?
- Insulin resistance and prediabetes usually cause no symptoms and can only be detected through blood tests – for example long-term sugar (HbA1c), fasting blood sugar or a glucose tolerance test. Anyone with risk factors such as abdominal fat, lack of exercise, a family history or PCOS should have their values checked by a doctor. This article serves educational purposes only and does not replace a medical diagnosis.
Sources
- New England Journal of Medicine (PMID 39536238)Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1)Clinical trial
- NIDDK – National Institute of Diabetes and Digestive and Kidney DiseasesInsulin Resistance & PrediabetesReference
- CDC – Centers for Disease Control and PreventionAbout Insulin Resistance and Type 2 DiabetesReference
This article is for information and education only. It does not replace medical advice and deliberately contains no dosing, usage or sourcing information.